Balyasny Asset Management’s CRISPR Therapeutics CRSP Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-83,467
| Closed | -$2.84M | – | 2081 |
|
|
2025
Q1 | $2.84M | Sell |
83,467
-810,468
| -91% | -$27.6M | ﹤0.01% | 1041 |
|
|
2024
Q4 | $35.2M | Buy |
893,935
+270,285
| +43% | +$10.6M | 0.05% | 336 |
|
|
2024
Q3 | $29.3M | Buy |
623,650
+532,986
| +588% | +$25M | 0.05% | 367 |
|
|
2024
Q2 | $4.9M | Buy |
+90,664
| New | +$4.9M | 0.01% | 823 |
|
|
2023
Q1 | – | Sell |
-64,580
| Closed | -$2.63M | – | 2271 |
|
|
2022
Q4 | $2.63M | Buy |
64,580
+42,018
| +186% | +$1.71M | 0.01% | 949 |
|
|
2022
Q3 | $1.48M | Buy |
+22,562
| New | +$1.48M | ﹤0.01% | 1264 |
|
|
2022
Q2 | – | Sell |
-7,016
| Closed | -$440K | – | 2364 |
|
|
2022
Q1 | $440K | Buy |
7,016
+1,169
| +20% | +$73.3K | ﹤0.01% | 1498 |
|
|
2021
Q4 | $443K | Sell |
5,847
-4,841
| -45% | -$367K | ﹤0.01% | 1423 |
|
|
2021
Q3 | $1.2M | Buy |
+10,688
| New | +$1.2M | 0.01% | 1072 |
|
|
2021
Q1 | – | Sell |
-3,418
| Closed | -$523K | – | 1612 |
|
|
2020
Q4 | $523K | Sell |
3,418
-96,384
| -97% | -$14.7M | ﹤0.01% | 970 |
|
|
2020
Q3 | $8.35M | Buy |
99,802
+93,839
| +1,574% | +$7.85M | 0.06% | 378 |
|
|
2020
Q2 | $438K | Buy |
+5,963
| New | +$438K | ﹤0.01% | 776 |
|
|
2019
Q3 | – | Sell |
-109,657
| Closed | -$5.17M | – | 1098 |
|
|
2019
Q2 | $5.17M | Buy |
+109,657
| New | +$5.17M | 0.03% | 507 |
|
|
2018
Q4 | – | Hold |
0
| – | – | – | 1325 |
|
|
2018
Q3 | – | Hold |
0
| – | – | – | 1482 |
|
|
2018
Q2 | – | Hold |
0
| – | – | – | 1639 |
|